CRIZOTINIB for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 1,724 adverse event reports in the FDA FAERS database where CRIZOTINIB was used for Non-small cell lung cancer.
Most Reported Side Effects for CRIZOTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 2,028 | 20.4% | 2,025 | 116 |
| Neoplasm progression | 1,161 | 11.7% | 350 | 222 |
| Nausea | 820 | 8.2% | 90 | 244 |
| Disease progression | 677 | 6.8% | 285 | 146 |
| Diarrhoea | 631 | 6.3% | 63 | 181 |
| Vomiting | 600 | 6.0% | 98 | 216 |
| Fatigue | 419 | 4.2% | 39 | 94 |
| Off label use | 353 | 3.6% | 107 | 76 |
| Dyspnoea | 352 | 3.5% | 110 | 180 |
| Visual impairment | 315 | 3.2% | 29 | 44 |
| Constipation | 313 | 3.2% | 42 | 99 |
| Decreased appetite | 304 | 3.1% | 48 | 114 |
| Oedema peripheral | 303 | 3.1% | 36 | 93 |
| Asthenia | 281 | 2.8% | 64 | 125 |
| Peripheral swelling | 278 | 2.8% | 30 | 67 |
Other Indications for CRIZOTINIB
Lung neoplasm malignant (1,949)
Lung adenocarcinoma (548)
Non-small cell lung cancer metastatic (429)
Neoplasm malignant (365)
Lung cancer metastatic (256)
Product used for unknown indication (167)
Lung adenocarcinoma stage iv (164)
Non-small cell lung cancer stage iv (151)
Anaplastic large cell lymphoma t- and null-cell types (139)
Lung carcinoma cell type unspecified stage iv (128)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)